During the long journey of drug development, there is a “Bermuda Triangle” that has caused countless scientists to sigh with regret—that is, the transition zone between success in the laboratory and failure in human clinical trials. Countless candidate drugs that showed miraculous results in mice failed in human trials. This “biological translation gap” is precisely the biggest invisible obstacle in the progress of modern medicine.
To break this deadlock, Creative Biolabs decided to look for answers at the microscopic level of life. Recently, the company announced a strategic upgrade of its non-human primate (NHP) biological sample library. Through a series of high-quality Cynomolgus monkey primary cells, it has built a bridge for global researchers to access the real physiological environment.
Searching for the “narrator” closest to humans
If drug development is a conversation, then choosing the right “participant” is of utmost importance. Although traditional rodents are cost-effective, their pulmonary anatomical structure, respiratory mucosal immune system, and endocrine regulatory mechanism do not fully correspond to the physiological language of humans.
“We need a ‘narrator’ who is more familiar with human physiological logic,” a researcher at Creative Biolabs pointed out. The Cynomolgus monkey, as an outstanding representative of non-human primates, has highly similar physiological characteristics to humans, making it the most ideal simulation object. In the vision of Creative Biolabs, establishing high-quality lung fibroblast cells and organ-specific cell libraries is not only about providing experimental materials, but also injecting real “life signals” into the research of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease (COPD).
The “craftsmanship” story behind each cell
The extraction and preservation of primary cells is itself a race against time and a final test of precise technology. Unlike ordinary cell lines, primary cells retain the most original and vivid memories of the organism, but they are also extremely fragile.
Creative Biolabs played the role of the “guardian” in this narrative. Through optimized ultra-low-temperature cryogenic technology, it ensures that cells retain astonishing biological activity after recovery. Before each batch of cells leaves the laboratory, they must pass through rigorous tests for purity (≥ 85%) and viability. This extreme pursuit of traceability and compliance ensures that every researcher receives not only the sample in the cryotube, but also a substantial commitment to scientific research.
In the complex field of thyroid research, the primary thyroid epithelial cells it has developed have become a powerful tool for studying hormone regulation and environmental interference, making the previously ambiguous endocrine responses become clearly observable in the in vitro model.
From the laboratory bench to the front line of life
“What we are doing is to ensure that every discovery in the laboratory can find its application in clinical practice.” This industry consensus is gradually becoming a reality thanks to the efforts of Creative Biolabs. In drug toxicology evaluation, using high-standard large airway epithelial cells for early screening is effectively reducing the risks and losses in the later stages of new drug development. Although the acquisition of high-quality NHP primary cells is fraught with challenges, the reliability of the data they provide is becoming a new driving force for innovative drug research.
About the Author
Creative Biolabs supports laboratory NHP preclinical studies with a wide array of biological products, including whole blood, serum, plasma, primary cells, tissue, body fluids, and recombinant reagents. As a specialized contract research organization, we offer diverse NHP disease models, providing biologicals from diseased primates. Recognizing the complexity and sensitivity of NHPs in biomedical research, we have developed specialized infrastructure and care to maintain their well-being. Despite the controversy surrounding NHP use, we ensure a steady supply and high-quality service to meet the urgent needs of biomedical research through our dedicated monitoring and evaluation platform.
